The history of pharmacologic treatment of obesity is characterizedby repetition: most drugs that have achieved regulatory approvaland reached the markets have subsequently been withdrawn owingto postmarketing discovery of serious adverse effects. In 2007,the cannabinoid-receptor antagonist rimonabant was not approvedby the Food and Drug Administration (FDA) and was withdrawnfrom the market in Europe because of an increased risk of depression,anxiety, and suicidal ideation1; the development program forseveral compounds of the same class that were in phase 3 studieshad to be terminated. In January of this year, the EuropeanMedicine Agency's Committee . . . [Full Text of this Article]
From the Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Denmark.